CD34 and chronic graft versus host disease: While an adequate CD34+ cell dose remains essential for ensuring engraftment and disease control, excessive doses greater than 8 × 106 CD34+ cells/kg may be associated with diminishing clinical benefit and increased transplant-related toxicity, particularly through elevated risks of chronic GVHD and NRM.